Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 11/20 | 0.49 |
| ▸ | EGFR | P00533 | 2/20 | 0.49 |
| ▸ | TEC | P42680 | 1/20 | 0.49 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.44 |
| ▸ | NTRK3 | Q16288 | 1/20 | 0.44 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.44 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.43 |
| ▸ | MKNK2 | Q9HBH9 | 2/20 | 0.43 |
| ▸ | TEAD1 | P28347 | 1/20 | 0.43 |
| ▸ | TEAD3 | Q99594 | 1/20 | 0.43 |
| ▸ | JAK3 | P52333 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22174268 | 0.92 | BTK (0.52) | BTKEGFRTECERBB2MKNK1 | |
| SCHEMBL22866410 | 0.85 | PDE4B (0.56) | BTKEGFRTECERBB2 | |
| SCHEMBL22446291 | 0.84 | KMO (0.47) | BTKEGFRTECERBB2TEAD1 | |
| SCHEMBL22446293 | 0.83 | EGFR (0.55) | BTKEGFRTECERBB2 | |
| SCHEMBL26365191 | 0.82 | BTK (0.43) | BTKEGFRTECNTRK1KCNH2 | |
| SCHEMBL22174105 | 0.82 | KMO (0.47) | BTKEGFRTECKCNH2ERBB2 | |
| SCHEMBL22446294 | 0.81 | BTK (0.52) | BTKEGFRERBB2TEAD1TEAD3 | |
| SCHEMBL22174118 | 0.80 | EPHX2 (0.58) | BTKEGFRTECTEAD1TEAD3 | |
| SCHEMBL22174221 | 0.79 | BTK (0.53) | BTKEGFRTECTEAD1TEAD3 | |
| SCHEMBL22173959 | 0.79 | EPHX2 (0.59) | BTKEGFRTECERBB2TEAD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | VIVIDION THERAPEUTICS, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | THE SCRIPPS RESEARCH INSTITUTE | 2021-01-07 | — | — | US | disclosed |
| US-10781239-B2 | In vivo engineered cereblon protein | VIVIDION THERAPEUTICS, INC. (US) | 2020-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11771689-B2 | Cereblon modulators and uses thereof | CRBN, CBFB, CNN2 | BTK 649/4885EGFR 1232/4885TEC 3852/4885 |
| US-20210002337-A1 | IN VIVO ENGINEERED CEREBLON PROTEIN | CRBN, CDR2, DCUN1D4 | BTK 3352/4885EGFR 4245/4885TEC 4370/4885 |
| US-10781239-B2 | In vivo engineered cereblon protein | CRBN, CDR2, DCUN1D4 | BTK 3352/4885EGFR 4245/4885TEC 4370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.